IDEXX Labs upgraded by Goldman with a new price target
$IDXX
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Goldman upgraded IDEXX Labs from Neutral to Buy and set a new price target of $435.00 from $530.00 previously
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/2/2024 | $500.00 | Outperform | Leerink Partners |
7/25/2024 | $580.00 | Buy | BTIG Research |
1/30/2024 | $525.00 | Overweight → Neutral | Piper Sandler |
12/7/2023 | $602.00 | Outperform | Exane BNP Paribas |
12/4/2023 | Neutral → Buy | Cleveland Research | |
8/2/2023 | $610.00 | Overweight → Neutral | Atlantic Equities |
7/25/2022 | $415.00 | Buy → Hold | Stifel |
7/21/2022 | $530.00 → $435.00 | Neutral → Buy | Goldman |
4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)